In 2020, a change of the terminology from NAFLD to metabolic associated fatty liver disease (MAFLD) has been proposed [20–22] and the diagnosis can be made in the presence of hepatic steatosis and at least one of the following criteria: (i) overweight or obesity, (ii) T2DM, and (iii) metabolic dysregulation (at least two factors among increased waist circumference, hypertension, hypertriglyceridemia, low serum HDL-cholesterol levels, impaired fasting plasma glucose, insulin resistance, or subclinical inflammation evaluated by high-sensitivity C-reactive protein (CRP) levels). The gene discussed is CRP; the disease is fatty liver disease.